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.RcTiew A r t i c l e 
The Role of Erythropoietin in the 
Anemia of Chronic Renal Failure 
N. Kevin Krane, M D * 
Tbe mayor factors responsible for the anemia of chronic 
renal failure are decreased erythropoietin (Ep) produc-
tion, the presence of inhibitors of erythropoiesis, blood 
loss, and hemolysis. Ep, which is produced in the kidney, 
probably exerts its effect on the colony-forming units of 
the erythrocyte. Ep levels fall with worsening renal func-
tion (creatinine clearances in the range of 2-40 ml/min). 
but they rise to their highest levels in the immediate 
predialysis period, probably due to severe ischemia of 
both renal and extrarenal production sites. When patients 
are begun on hemodialysis, Ep levels fall, and the hema-
tocrit rises. Erythropoietin therapy in the management of 
anemia of chronic renal failure is potentially a practical 
application of experimental studies. 
A n e m i a , an almost invariable feature of chronic renal 
failure, usually develops when creatinine levels are 
greater than 3.5 mg /d l , or creatinine clearance is less 
than 40 ml/min/1.73m2 (1). Except in many patients who 
have polycystic kidney disease, the anemia worsens as 
renal funct ion deteriorates, and end-stage renal failure is 
reached. After this has occurred, the degree of anemia 
remains relatively constant, although it may actually 
improve when the patient is placed on hemodialysis. 
In general, anemia is better tolerated in chronic renal 
failure than in other chronic illnesses. This tolerance has 
been attr ibuted to acidemia and to elevated 2,3 DPG 
levels, which lower hemoglobin-oxygen affinity and 
facilitate release of oxygen to the tissues (2,3). Symptoms 
usually occur in those patients wi th underlying pulmo-
nary disease or w i th vascular insuf f ic iency, which 
decreases cardiac or cerebral blood f low. 
The anemia of chronic renal failure is a normochromic, 
normocytic anemia characterized by a decreased reticu-
locyte index, the appearance of burr cells in the peri-
pheral blood smear, and a " n o r m a l " bone marrow mor-
phology. The response o f the marrow is actually impaired 
because erythropoiesis in individuals with a similar 
degree of anemia is much more active. 
The anemia of renal failure has many causes, and sev-
eral factors contr ibute to its severity. The major causes 
are: 1) decreased erythropoiet in (Ep) p roduct ion ; 2) 
presence of inhibi tors of erythropoiesis; 3) b lood loss; 
and 4) hemolysis. 
Inhibitors of Erythropoiesis 
Bone marrow fai lure, due in part to decreased Ep pro-
duct ion , may also be caused by the presence of inhib i -
tors of erythropoiesis in uremic serum. Serum from 
patients wi th uremia is capable of inhib i t ing the rate of 
erythropoiesis by both human and animal erythroblasts 
in cul ture. The inhibitors do not inactivate or interfere 
wi th the action of Ep, but, as shown by experiments 
wi th cells in cul ture, they inhibi t erythroblast protein 
synthesis (4). To demonstrate the importance of these 
inhibi tors, Wal Iner and Vautr in (5) compared the ability 
of serum f rom uremic patients and controls to inhibi t 
heme synthesis by rabbit marrow cultures and ery-
th ro id colony format ion by mouse marrow cul ture. As 
renal funct ion worsened and hematocri t fe l l , serum 
inhib i tor levels rose, as measured by the in vi tro sys-
tems. Conversely, i nh ib i to r concent ra t ions fel l in 
patients whose hematocrit rose after beginning hemo-
dialysis. Apparent ly, wi th worsening renal fai lure, con-
centration of a dialyzable inhibi tor increases, contr ibut-
ing to marrow suppression. 
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Ohno, et al observed that sera from undialyzed anemic, 
uremic patients significantly inhibited erythroid colony-
forming units in rabbits marrows, wi th reduction in the 
erythroid precursors or burst-forming units (BFU) (6). 
After dialysis, the inhibitors of colony-forming units-
erythroid (CFU-E) were markedly reduced in the serum 
of three of four patients. The BFU were not measured. 
Whether a single inhibitor of erythropoiesis is capable of 
inhibi t ing both types of erythroid colony-forming cells 
(CFU-E and BFU-E) or whether two different specific 
inhibitors are present was not established. 
Blood Loss in Chronic Renal Failure 
Excessive blood loss may be due to: 1) gastrointestinal 
mucosal bleeding due to platelet defects; 2) phlebotomy 
for laboratory studies; 3) surgical procedures; or 4) 
blood loss during dialysis. Usingtechnetium-labeled red 
blood cells and six different dialyzers, Ireland, et al (7) 
concluded that the annual whole blood loss from all 
causes was 5.3L, wi th 1.606 ml f rom gastrointestinal loss, 
540 ml f rom blood sampling, and a min imum of 3,180 ml 
f rom dialysis procedures. During dialysis, blood may be 
trapped, slowing blood f low and leading to the devel-
opment of thrombus on the dialysis membrane. 
Hemolysis 
Average red cell survival determined by ^ichromium 
tagging is reported to be 63 days in uremic patients 
compared to 98 days in a control group (8). The short-
ened red cell survival has been conf i rmed by other tech-
niques including a bi l i rubin turnover method (9). Several 
factors responsible for this problem include impaired 
erythrocyte pentose phosphate enzymes in uremia, and 
microangiopathic changes in some patients that permit 
intravascular trauma to the red cells. Signs of hemolysis 
may be evident in these patients. 
The causes of hemolysis in patients with chronic renal 
failure (10) include: 
1. Erythrocyte sodium pump inhibi t ion by uremic 
plasma 
2. Microangiopathy 
3. Decreased intraerythrocytic pentose phosphate 
shunt activi ty due to : a) G6PD def ic iency; 
b) chloramine in tapwater used in hemodialysis; 
c) drugs with oxidizing potential 
4. Red blood cell rigidity due to hypophosphatemia 
5. Decreased filterability of red blood cells 
6. Hypersplenism 
7. Thermal injury 
8. Increased serum concentration of copper, alum-
inum, or zinc 
Erythropoietin 
Impaired ability of the diseased kidney to produce Ep is 
one factor contr ibut ing to bone marrow failure in 
chronic renal failure. It has been postulated that the 
kidney produces an enzyme that reacts with a plasma 
substrate to produce Ep. However, active Ep can be 
found in the perfusate after perfusion of isolated kidneys 
with a serum free medium. Biologically active Epcan also 
be extracted from bovine kidneys homogenized in a 
neutrally buffered solution. 
The actual site of Ep production has not been identif ied. 
Fluorescin-labeled globulins against crude Ep localize to 
the g lomerul i ; however, because other antibodies may 
localize there, the glomerul i have not proved to be the 
site of Ep product ion. The juxtaglomerular apparatus 
(JGA) has been proposed as the renal source for Ep 
because some patients with Bartter's syndrome, who 
have hyperplasia of the JGA, have erythrocytosis and 
elevated plasma Ep levels. Finally, the renal medulla has 
been considered as a possible site because Ep produc-
t ion increases when intramedullary pressure rises. The 
liver produces Ep dur ing early development, in states of 
hypoxia, or in adults after nephrectomy. In some patients 
with renal failure, the liver may contr ibute significantly 
to Ep product ion. With liver damage, e.g., viral or toxic 
hepatitis, anemia of chronic renal failure may temporar-
ily improve, presumably f rom product ion of erythro-
poietin by regenerating liver cells (11). As will be dis-
cussed later, extrarenal sites of Ep product ion may be 
important in the response to severe tissue ischemia dur-
ing renal failure. 
Ep product ion depends on the plasma pOs, hemo-
globin oxygen saturation, hemoglobin concentrat ion, 
b lood f low, erythrocyte 2,3 DPG levels, and the basal 
metabolic rate (10). 
In v i t ro, Ep induces the earliest erythroid precursors 
BFU-E, but it has l itt le effect on BFU-E in vivo. The 
colony-forming units, presumably derived from the 
BFU, are very sensitive to Ep both in vivo and in vi tro. 
The CFU-E are therefore felt to be the primary site at 
which Ep exerts its erythropoiet ic effect. Whether Ep 
can affect the mult ipotential hematopoietic stem cell 
(CFU-S) is uncertain. 
Erythropoietin is a glycoprotein that can be assayed in 
either the plasma or urine. However, the urinary Ep assay 
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is not valid in patients with renal failure because little is 
known about Ep excretion. Assays for plasma Ep have 
been slow to develop because it is dif f icult to obtain 
sufficient quantities of purif ied bioactive Ep f rom kidney 
extracts. For this reason, animal cell culture bioassays 
and a hemagglutination inhibi t ion assay have been 
employed. Recently, purif ication of human Ep f rom the 
urine of patients with aplastic anemia has provided small 
quantities of highly bioactive Ep (70,000 U/mg) (12). 
In 1981, Zaroulis, et al evaluated Ep levels in polycythe-
mia vera, aplastic anemia, and chronic renal failure (13). 
Their radioimmunoassay (RIA) for Ep used highly pur i -
fied radio-iodinated Ep as tracer, while antisera were 
generated in rabbits using less pure Ep (62 U/mg) as 
antigen. Ep levels were low in patients with polycythemia 
vera and high in those with aplastic anemia, indicating 
that the assay was sufficiently sensitive and specific. They 
evaluated 19 normal individuals, 9 patients with severe 
aplastic anemia, 3 with untreated polycythemia vera, and 
11 chronic hemodialysis patients. 
In normal patients, Ep levels ranged from 18-81 with a 
mean of 29 m U / m l . I n patients with severe aplastic ane-
mia, levels of Ep were markedly elevated (mean value of 
3,487 mU/ml ) , whi le in the three patients with poly-
cythemia, the mean level was 18 m U / m l . In patients with 
serum creatinine concentrations of 5-17 mg/d l , serum Ep 
ranged f rom 18-115 m U / m l (mean of 40.5) before hemo-
dialysis. The degree of anemia was also highly variable. 
The wide range of Ep may have been due to variability in 
both the degree of anemia and residual renal funct ion. 
Synthesis of Ep might be increased by the anemia or 
decreased secondary to impaired kidney funct ion. 
Radtke, et al (1) used a fetal mouse liver cell assay to 
measure the serum Ep levels of 135 patients with varying 
degrees of chronic renal fai lure; they compared these 
with values obtained in 59 healthy controls. A first group 
of renal patients received no blood transfusions or iron 
therapy and did not need hemodialysis.They wereclassi-
fied in subgroups according to residual excretory renal 
funct ion indicated by creatinine clearance (Cr Cl): 2-9 
m l /m in , 10-19 m l /m in , 20-29 m l /m in , 30-39 m l /m in , and 
40-90 m l /m in . A second group of patients had endstage 
renal disease (ESRD) and were investigated two to six 
months before the onset of regular hemodialysis, imme-
diately before, and two to six months after the first 
hemodialysis. Dialysis was performed three to four times 
for six to eight hours a week using various disposable 
dialyzers. The patients received no transfusions. 
The development of anemia correlated with the pro-
gression of renal insufficiency, becoming manifest in 
patients with a Cr Cl below 40 ml/min/1.73 m^. Between 
2 and 40 m l /m in , the Cr Cl and hematocrit were highly 
significantly correlated, but with clearances between 41-
90 ml /m in there was no correlation. 
In this study the mean Ep concentration and hematocrit of 
each subgroup were compared to those of healthy con-
trols. The Ep concentrations were significantly elevated in 
all subgroups. The highest value, found in patients with Cr 
Cl between 20-29 ml /min , was not exceeded despite wors-
ening anemia and lower Cr Cl. Between 2-40 ml /min Cr 
Cl, the correlation between Cr Cl and serum Ep concen-
tration was significant, with a parallel decrease of excre-
tory and endocrine renal function. 
In patients with endstage renal failure, hematocrit de-
creased before dialysis and increased after dialysis was 
started. However, Ep concentrations increased in the 
predialysis period as hematocrit fell and decreased after 
hemodialysis began. The lowest Ep levels were found in 
those patients who had received dialysis for more than 
six months. 
Koch and Radtke, using a fetal mouse liver cell bio-
assay, found Ep levels in one hundred anemic hemodi-
alysis patients to be as low as those of normal patients. 
This observation supports the f ind ing that renal endo-
crine funct ion deteriorates as renal excretory funct ion 
deteriorates (14). 
Radtke also measured Ep levels and hematocrit in 42 
patients with endstage renal disease immediately before 
treatment and after init iation of dialysis, comparing 
results wi th those in 59 controls (15). All dialysis patients 
received iron therapy, but no blood transfusions or 
androgens had been given. Mean Ep concentrations 
before and after dialysis were significantly higher than 
those of the normal controls, whi le hematocrit levels 
were significantly lower, as expected. Radtke postulated 
that the high levels of Ep before dialysis were a response 
to the severe tissue hypoxia f rom anemia, as well as to 
f luid overload with cardiorespiratory insufficiency. This 
paradoxical rise in erythropoietin despite worsening 
renal funct ion has been reported previously to originate 
f rom nonrenal product ion (16). The Ep levels fell after 
three months of regular hemodialysis. When the hypoxic 
stimulus was less severe, the Ep levels were not as greatly 
elevated relative to the degree of anemia. In patients 
who had comparable anemia wi thout renal disease, the 
Ep levels were much higher. In some patients, the fall in 
Ep after dialysis was started may have resulted f rom 
worsening intrinsic renal failure. 
In endstage renal failure, the regulatory feedback between 
hypoxia and Ep continues, but it operates at a lower 
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level. The rise in hematocrit that occurs wi th hemodialy-
sis does not appear to be due to an increase in renal or 
extrarenal Ep, because Ep levels continue to fall. 
De Klerk, et al reported erythropoiet in titers in patients 
with chronic renal failure: 45 were receiving conserva-
tive therapy, and 54 were on maintenance hemodialysis 
(17). Using a fetal mouse liver cell bioassay, they found 
that Ep levels were significantly below normal in both 
groups. The causes of renal failure seemed to make a 
difference. A significant inverse relationship between Ep 
level and hemoglobin concentration was found in pre-
dialysis patients with chronic glomerulonephrit is but not 
in patients with nonglomerular disease. Ep levels did not 
differ significantly between anephric dialysis patients 
and the nephric patients dependent on blood transfu-
sions. However, the dialysis patients dependent on trans-
fusions had significantly lower Ep and hemoglobin levels 
than those patients who were not dependent on transfu-
sions. In the latter group, Ep levels correlated positively 
with the level of hemoglobin, a correlation not found in 
those patients dependent on transfusions. 
Elevated Ep concentrations found in glomerular disease 
suggest that in these patients the oxygen sensor mechan-
ism is functionally intact and is located outside the 
glomerulus. Renal medullary interstitial cells may serve 
as a sensor to stimulate Ep product ion, by releasing renal 
prostaglandins into the circulation in response to hypoxia. 
Demonstrations by Mujovicand Fisherthat indomethacin 
suppresses Ep production in hypoxic dogs support this 
theory (18). De Klerk suggested that the poor correlation 
between Epand hematocrit in some patients might result 
f rom factors such as erythropoietic inhibitors, for eryth-
ropoietin is still detectable, although levels are below 
normal (15). 
Summary 
The role of erythropoiet in in the anemia of renal failure 
can be summarized as follows: 
1. Erythropoietin is probably produced in the k id-
ney, site unknown. 
2. Renal anemia develops at a creatinine clearance 
of less than 40 ml/min/1.73 m^. 
3. Erythropoietin levels correlate positively with 
creatinine clearance between 2-40 ml /m in . 
4. Erythropoietin levels are at their highest in the 
period immediately before dialysis. 
5. Serum erythropoietin concentrationsfall to levels 
slightly above normal controls after at least 3 
months of hemodialysis. 
The implications for therapy are quite important. Can 
erythropoiet in therapy improve anemia? Van Stone 
administered erythropoiet in to anephric, peritoneally 
dialyzed rats for 12 days. Treated rats had greater than 
three times more bone marrow red cell precursors and 
two times greater plasma iron turnover than did saline 
injected anephric rats (19). The hematocrit was also sig-
nificantly higher than in uremic rats not treated with Ep, 
although still lower than the nonuremic control group. 
Studies of Ep treatment in humans are still for thcoming. 
The complex role that erythropoiet in plays in the devel-
opment of renal failure is unfolding. When erythropoie-
tin becomes available for clinical use, it should contr ib-
ute greatly to treatment of anemia in the dialysis patient. 
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